Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.
Many IBD patients on advanced drugs still struggle with disease burden in real life, highlighting need for additional treatment options.
This Greek real-world patient survey reveals that IBD patients receiving advanced therapies continue to experience substantial disease burden, suggesting that current treatment paradigms fail to achieve satisfactory disease control outside clinical trial settings for a substantial proportion of patients. These findings reinforce the unmet need for additional therapeutic options and improved treatment optimization strategies in IBD.
What the study was
- Study design
- Cross-sectional patient-reported survey
- Population
- IBD patients (Crohn's disease and ulcerative colitis) on advanced therapies in Greece
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Frontiers in Immunology
Why it surfaced
Real-world evidence of persistent unmet need in IBD despite advanced therapies; PMC open-access; supports T9 rare disease/unmet need monitoring signal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.